Skip to Main content Skip to Navigation
Journal articles

Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer

Abstract : Fluoropyrimidine (FP) plus platinum chemotherapy has been recently established as a second-line (L2) preferred option in advanced biliary tract cancer (aBTC) (ABC-06 phase III trial). However, the overall survival (OS) benefit was limited and comparison with FP monotherapy was not available. Our aim was to assess the OS of patients treated with a FP monotherapy compared to a doublet with irinotecan or platinum in L2. We performed a retrospective analysis of two large multicenter prospective cohorts: a French cohort (28 centers) and an Italian cohort (9 centers). All consecutive patients with aBTC receiving FP-based L2 after gemcitabine plus cisplatin/gemcitabine plus oxaliplatin L1 between 2003 and 2016 were included. A subgroup analysis according to performance status (PS) and an exploratory analysis according to platinum sensitivity in L1 were planned. In the French cohort (n = 351), no significant OS difference was observed between the FP monotherapy and doublet groups (median OS: 5.6 vs 6.8 months, P = .65). Stratification on Eastern Cooperative Oncology Group (ECOG) PS showed similar results in PS 0-1 and 2. Median OS was not different between FP monotherapy, platinum- and irinotecan-based doublets (5.6 vs 7.1 vs 6.7 months, P = .68). Similar findings were observed in the Italian cohort (n = 174) and in the sensitivity analysis in pooled cohorts (n = 525). No L2 regimen seemed superior over others in the platinum resistant/refractory or sensitive subgroups. Our results suggest that FP monotherapy is as active as FP doublets in aBTC in L2, regardless of the patient PS and country, and could be a therapeutic option in this setting.
Document type :
Journal articles
Complete list of metadatas

Cited literature [26 references]  Display  Hide  Download

https://hal-univ-rennes1.archives-ouvertes.fr/hal-02929354
Contributor : Laurent Jonchère <>
Submitted on : Thursday, September 10, 2020 - 11:34:23 AM
Last modification on : Wednesday, October 14, 2020 - 4:08:48 AM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : 2020-12-11

Please log in to resquest access to the document

Identifiers

Citation

Cindy Neuzillet, Andrea Casadei‐gardini, Bertrand Brieau, Caterina Vivaldi, Giovanni Brandi, et al.. Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer. International Journal of Cancer, Wiley, 2020, ⟨10.1002/ijc.33146⟩. ⟨hal-02929354⟩

Share

Metrics

Record views

19